Feed aggregator

Common HIV treatments may aid Alzheimer's disease patients

World Pharma News - Wed, 04/17/2024 - 10:00
Alzheimer's disease (AD) currently afflicts nearly seven million people in the U.S. With this number expected to grow to nearly 13 million by 2050, the lack of meaningful therapies represents a major unmet medical need. Scientists at Sanford Burnham Prebys have now identified promising real-world links between common HIV drugs and a reduced incidence of AD. The study, led by Jerold Chun, M.D., Ph.D., was published in Pharmaceuticals.

Chun's new research builds on his lab's landmark publication in Nature in 2018 that described how somatic gene recombination in neurons can produce thousands of new gene variants within Alzheimer's disease brains.

Lilly Eyes Zepbound Label Expansion After Clearing Phase III Sleep Apnea Study

Biospace news - Wed, 04/17/2024 - 02:00
Lilly Eyes Zepbound Label Expansion After Clearing Phase III Sleep Apnea Study 4/17/2024

Sage Axes Parkinson’s Program for Dalzanemdor After Phase II Flop

Biospace news - Wed, 04/17/2024 - 02:00
Sage Axes Parkinson’s Program for Dalzanemdor After Phase II Flop 4/17/2024

Amylyx Sheds More Light on Relyvrio’s Late-Stage Trial Failure in ALS

Biospace news - Wed, 04/17/2024 - 02:00
Amylyx Sheds More Light on Relyvrio’s Late-Stage Trial Failure in ALS 4/17/2024

Amylyx at a Crossroads: Can the Company Overcome the Loss of Relyvrio?

Biospace news - Wed, 04/17/2024 - 02:00
Amylyx at a Crossroads: Can the Company Overcome the Loss of Relyvrio? 4/17/2024

Arvinas Strikes Deals With Pfizer, Novartis to Compete in Protein Degrader Space

Biospace news - Wed, 04/17/2024 - 02:00
Arvinas Strikes Deals With Pfizer, Novartis to Compete in Protein Degrader Space 4/17/2024

Top Q1 Series A Investments Highlight VC Rebound in Biopharma

Biospace news - Wed, 04/17/2024 - 02:00
Top Q1 Series A Investments Highlight VC Rebound in Biopharma 4/17/2024

Canaan Secures More Than $100M in New Biopharma Funding, Adds Former Pfizer Executive

Biospace news - Wed, 04/17/2024 - 02:00
Canaan Secures More Than $100M in New Biopharma Funding, Adds Former Pfizer Executive 4/17/2024

Cullinan Targets Autoimmune Market, Nabs $280M in Private Placement

Biospace news - Wed, 04/17/2024 - 02:00
Cullinan Targets Autoimmune Market, Nabs $280M in Private Placement 4/17/2024

GSK Touts Late-Stage Antibiotic Win in Gonorrhea, Long-Term Shingrix Vaccine Data

Biospace news - Wed, 04/17/2024 - 02:00
GSK Touts Late-Stage Antibiotic Win in Gonorrhea, Long-Term Shingrix Vaccine Data 4/17/2024

Arrowhead’s Plozasiran Poised for Dyslipidemia Market, $700M in Sales by 2032: GlobalData

Biospace news - Wed, 04/17/2024 - 02:00
Arrowhead’s Plozasiran Poised for Dyslipidemia Market, $700M in Sales by 2032: GlobalData 4/17/2024

Amylyx and ALS, Continued ADC Excitement, Dire Drug Shortages

Biospace news - Wed, 04/17/2024 - 02:00
Amylyx and ALS, Continued ADC Excitement, Dire Drug Shortages 4/17/2024

C-Suite Shuffle: Bayer Continues Leadership Shakeup with Hires at Subsidiaries

Biospace news - Wed, 04/17/2024 - 02:00
C-Suite Shuffle: Bayer Continues Leadership Shakeup with Hires at Subsidiaries 4/17/2024

AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson's disease

World Pharma News - Tue, 04/16/2024 - 10:00
Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, on Sunday April 14 presented results from the 18-month Phase Ib clinical trial for AB-1005, an investigational gene therapy for treating patients with Parkinson's disease (PD).(1,2) The data were presented at the American Academy of Neurology 2024 Annual Meeting in Denver, Colorado, USA.

The study met its primary objective, which was to evaluate the safety of a one-time bilateral delivery of AB-1005 directly to the putamen.

J&J Narrowly Misses Q1 Revenue on Lower-Than-Expected Stelara Sales

Biospace news - Tue, 04/16/2024 - 02:00
J&J Narrowly Misses Q1 Revenue on Lower-Than-Expected Stelara Sales 4/16/2024

Sandoz’s Biosimilar Skyrockets After CVS Removes AbbVie’s Humira from Formularies

Biospace news - Tue, 04/16/2024 - 02:00
Sandoz’s Biosimilar Skyrockets After CVS Removes AbbVie’s Humira from Formularies 4/16/2024

Boehringer Ingelheim Aims to Bring 25 New Products to Market by 2030

Biospace news - Tue, 04/16/2024 - 02:00
Boehringer Ingelheim Aims to Bring 25 New Products to Market by 2030 4/16/2024

Novartis Secures Phase III Fabhalta Win in IgAN as FDA Starts Priority Review

Biospace news - Tue, 04/16/2024 - 02:00
Novartis Secures Phase III Fabhalta Win in IgAN as FDA Starts Priority Review 4/16/2024

Intra-Cellular Touts Phase III Major Depressive Disorder Results for Antipsychotic Drug

Biospace news - Tue, 04/16/2024 - 02:00
Intra-Cellular Touts Phase III Major Depressive Disorder Results for Antipsychotic Drug 4/16/2024

Ultragenyx Eyes Pivotal Study After Mid-Stage Win in Angelman Syndrome

Biospace news - Tue, 04/16/2024 - 02:00
Ultragenyx Eyes Pivotal Study After Mid-Stage Win in Angelman Syndrome 4/16/2024